ClinicalTrials.gg
CompletedNCT05176639THRIVEUpdated Aug 13, 2026Results posted

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

A Phase 3 interventional study of Veligrotug and Placebo in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Completed at 53 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
14th of 47
113 · median 84
Started
2022
with 4 others
Phase 3
21 of 53
3 open now
Registered
17th of 53
by date
Lead sponsor
9 of 53
Viridian Therapeutics, Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 14th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 17th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with thyroid eye disease (TED). The primary objective of this clinical trial is to establish the safety, tolerability, and efficacy of veligrotug, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of veligrotug in active TED participants who received 10 milligrams (mg)/kilogram (kg).

03

Conditions studied

  • Thyroid Eye Disease

Keywords

  • Thyroid Eye Disease
  • Thyroid-Associated Ophthalmopathy
  • Dysthyroid Ophthalmopathy
  • Graves Eye Disease
  • Graves Orbitopathy
  • Myopathic Ophthalmopathy
  • Congestive Ophthalmopathy
  • Edematous Ophthalmopathy
  • Infiltrative Ophthalmopathy
  • Thyroid-Associated Orbitopathy
  • Graves Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Active TED Participants (THRIVE):

  • Must have moderate to severe active TED with documented evidence of ocular symptoms or signs that began within 15 months prior to screening
  • Must have Clinical Activity Score (CAS) of ≥ 3 on the 7-item scale for the study eye
  • Must agree to use highly effective as specified in the protocol
  • Female TED participants must have a negative serum pregnancy test at screening

Key Exclusion Criteria for Active TED Participants (THRIVE):

  • Must not have received prior treatment with another anti-IGF-1R therapy or any agent for TED
  • Must not have used systemic or selenium within 2 weeks prior to Day 1
  • Must not have received rituximab, tocilizumab or other agents or any other therapy for TED within 8 weeks prior to Day 1
  • Must not have received an investigational agent for any condition within 8 weeks prior to Day 1
  • Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the Investigator would confound interpretation of the study results
  • Must not have had previous orbital irradiation or surgery for TED in the study eye
  • Must not have a history of inflammatory bowel disease
  • Must not have a history of or screening audiometry assessment of (as determined by investigator) ear pathology, relevant ear surgery, or hearing loss
  • Female TED participants must not be pregnant or lactating

Note: Prior thyroidectomy, radioactive iodine (RAI) treatment, or orbital decompression surgery limited to bone only are NOT exclusions.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Veligrotug

    Participants will receive veligrotug 10 mg/kg as an intravenous (IV) infusion every 3 weeks (Q3W) for 12 weeks.

    Drug: Veligrotug

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to veligrotug as an IV infusion Q3W for 12 weeks.

    Drug: Placebo

Interventions

  • 5 IV Infusions of veligrotug 10 mg/kg

    Also known as: VRDN-001

  • DrugPlacebo

    5 IV Infusions of veligrotug matched placebo

06

What researchers measure

Primary outcomes

  1. Proptosis Responder Rate (PRR) in the Study Eye As Measured by Exophthalmometer

    Proptosis responder in the study eye was defined as a reduction of proptosis of ≥2 millimeters (mm) from baseline in the study eye (without a corresponding increase of ≥2 mm in the fellow eye) as measured by exophthalmometer. Missing data were imputed with the Multiple Imputation method.

    Time frame: Baseline to Week 15

Secondary outcomes

  1. Change From Baseline in Proptosis in the Study Eye As Measured by Exophthalmometer

    Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in mm, measured using an exophthalmometer. Missing data were imputed with the Multiple Imputation method.

    Time frame: Baseline, Week 15

  2. PRR in the Most Proptotic Eye As Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)

    Proptosis responder in the most proptotic eye by MRI/CT was defined as a reduction of proptosis of ≥2 mm from baseline in the most proptotic eye by MRI/CT (without a corresponding increase of ≥2 mm in the other eye) as measured by MRI/CT. Missing data were imputed using the Exophthalmometer Imputation method, as applicable.

    Time frame: Week 15

  3. Change From Baseline in Proptosis in the Most Proptotic Eye As Measured by MRI/CT

    Measurement of proptosis conducted by the central imaging reading center using MRI/CT of the orbits acquired without contrast. Measurements were conducted by 2 independent readers with adjudication if the difference between the 2 primary readers in proptosis measurement exceeded 5% (calculated as the difference divided by the larger measurement). The average of 2 (or 3 if adjudicated) measurements were used for analyses. Missing data were imputed using the Exophthalmometer Imputation method, as applicable.

    Time frame: Baseline, Week 15

  4. Change From Baseline in CAS in the Study Eye

    The CAS was based on 7 components: spontaneous retrobulbar pain, pain on attempted eye movements (upward, side to-side, and downward gazes), conjunctival redness, redness of the eyelids, chemosis, swelling of the caruncle or plica and swelling of the eyelids. Each component was scored as present or absent (scored as 1 or 0, respectively), and the CAS was given as the sum of the scores (range, 0 to 7, with higher scores indicating greater level of inflammation). Missing data were imputed with the Multiple Imputation method.

    Time frame: Baseline, Week 15

  5. Overall Responder Rate (ORR) Comprising of PRR and Clinical Activity Responder Rate in the Study Eye

    ORR in the study eye was comprised of PRR in the study eye (reduction of proptosis of ≥ 2 mm from baseline \[without a corresponding increase of ≥ 2 mm in the fellow eye\]) and clinical activity responder in the study eye (reduction in clinical activity score \[CAS\] ≥ 2 points from baseline \[without a corresponding increase of ≥ 2 points in the fellow eye\]). CAS ranged from 0 to 7, with higher scores indicating greater level of inflammation. Proptosis (distance between the lateral orbital rim and the most anterior position of the cornea in mm) was measured using an exophthalmometer. Missing data were imputed with Multiple Imputation method.

    Time frame: Baseline to Week 15

  6. Clinical Activity Responder Rate in the Study Eye

    Clinical activity responder rate in the study eye was defined as a reduction in CAS ≥2 points from baseline in the study eye (without a corresponding increase of ≥2 points in the fellow eye). Missing data were imputed with the Multiple Imputation method.

    Time frame: Week 15

  7. Diplopia Responder Rate

    Diplopia responder was defined as reduction in Gorman subjective diplopia score of ≥1 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the Multiple Imputation method.

    Time frame: Week 15

  8. Diplopia Resolution Rate

    Diplopia resolution was defined as reduction in Gorman subjective diplopia score to 0 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the Multiple Imputation method.

    Time frame: Week 15

  9. Percentage of Participants With a CAS of 0 or 1 in the Study Eye

    The CAS was based on 7 components: spontaneous retrobulbar pain, pain on attempted eye movements (upward, side to-side, and downward gazes), conjunctival redness, redness of the eyelids, chemosis, swelling of the caruncle or plica and swelling of the eyelids. Each component was scored as present or absent (scored as 1 or 0, respectively), and the CAS was given as the sum of the scores (range, 0 to 7, with higher scores indicating greater level of inflammation). Missing data were imputed with the Multiple Imputation method.

    Time frame: Week 15

07

Results

Posted Aug 13, 2026

Participant flow

As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. The primary and secondary efficacy analyses and safety analysis were measured in the pre-specified study eye per individual participant.

Participant flow — Overall Study
MilestoneVeligrotugPlacebo
Started7538
Received at least 1 dose of study drug7538
Completed464
Not completed2934
Withdrew: Enrolled in open-label extension study1230
Withdrew: Lost to follow-up70
Withdrew: Withdrawal by subject44
Withdrew: Failure to adhere to protocol requirements30
Withdrew: Adverse event20
Withdrew: Worsening of the disease10

Outcome measures

PrimaryProptosis Responder Rate (PRR) in the Study Eye As Measured by Exophthalmometer

Proptosis responder in the study eye was defined as a reduction of proptosis of ≥2 millimeters (mm) from baseline in the study eye (without a corresponding increase of ≥2 mm in the fellow eye) as measured by exophthalmometer. Missing data were imputed with the Multiple Imputation method.

Time frame:
Baseline to Week 15
Reported as:
Number · percentage of participants
Proptosis Responder Rate (PRR) in the Study Eye As Measured by Exophthalmometer
percentage of participantsVeligrotugPlacebo
Proptosis Responder Rate (PRR) in the Study Eye As Measured by Exophthalmometer70.005.26
Statistical analysis
  • Veligrotug vs Placebo · Regression, Logistic · p = <0.0001 · Risk difference (rd): 64.74 · 95% CI 51.97 to 77.51
SecondaryChange From Baseline in Proptosis in the Study Eye As Measured by Exophthalmometer

Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in mm, measured using an exophthalmometer. Missing data were imputed with the Multiple Imputation method.

Time frame:
Baseline, Week 15
Reported as:
Least squares mean · mm
Change From Baseline in Proptosis in the Study Eye As Measured by Exophthalmometer
mmVeligrotugPlacebo
Change From Baseline in Proptosis in the Study Eye As Measured by Exophthalmometer-2.90 ± 0.18-0.48 ± 0.24
SecondaryPRR in the Most Proptotic Eye As Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)

Proptosis responder in the most proptotic eye by MRI/CT was defined as a reduction of proptosis of ≥2 mm from baseline in the most proptotic eye by MRI/CT (without a corresponding increase of ≥2 mm in the other eye) as measured by MRI/CT. Missing data were imputed using the Exophthalmometer Imputation method, as applicable.

Time frame:
Week 15
Reported as:
Number · percentage of participants
PRR in the Most Proptotic Eye As Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)
percentage of participantsVeligrotugPlacebo
PRR in the Most Proptotic Eye As Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)70.799.36
SecondaryChange From Baseline in Proptosis in the Most Proptotic Eye As Measured by MRI/CT

Measurement of proptosis conducted by the central imaging reading center using MRI/CT of the orbits acquired without contrast. Measurements were conducted by 2 independent readers with adjudication if the difference between the 2 primary readers in proptosis measurement exceeded 5% (calculated as the difference divided by the larger measurement). The average of 2 (or 3 if adjudicated) measurements were used for analyses. Missing data were imputed using the Exophthalmometer Imputation method, as applicable.

Time frame:
Baseline, Week 15
Reported as:
Least squares mean · mm
Change From Baseline in Proptosis in the Most Proptotic Eye As Measured by MRI/CT
mmVeligrotugPlacebo
Change From Baseline in Proptosis in the Most Proptotic Eye As Measured by MRI/CT-2.96 ± 0.19-0.58 ± 0.27
SecondaryChange From Baseline in CAS in the Study Eye

The CAS was based on 7 components: spontaneous retrobulbar pain, pain on attempted eye movements (upward, side to-side, and downward gazes), conjunctival redness, redness of the eyelids, chemosis, swelling of the caruncle or plica and swelling of the eyelids. Each component was scored as present or absent (scored as 1 or 0, respectively), and the CAS was given as the sum of the scores (range, 0 to 7, with higher scores indicating greater level of inflammation). Missing data were imputed with the Multiple Imputation method.

Time frame:
Baseline, Week 15
Reported as:
Least squares mean · units on a scale
Change From Baseline in CAS in the Study Eye
units on a scaleVeligrotugPlacebo
Change From Baseline in CAS in the Study Eye-3.42 ± 0.16-1.70 ± 0.22
SecondaryOverall Responder Rate (ORR) Comprising of PRR and Clinical Activity Responder Rate in the Study Eye

ORR in the study eye was comprised of PRR in the study eye (reduction of proptosis of ≥ 2 mm from baseline \[without a corresponding increase of ≥ 2 mm in the fellow eye\]) and clinical activity responder in the study eye (reduction in clinical activity score \[CAS\] ≥ 2 points from baseline \[without a corresponding increase of ≥ 2 points in the fellow eye\]). CAS ranged from 0 to 7, with higher scores indicating greater level of inflammation. Proptosis (distance between the lateral orbital rim and the most anterior position of the cornea in mm) was measured using an exophthalmometer. Missing data were imputed with Multiple Imputation method.

Time frame:
Baseline to Week 15
Reported as:
Number · percentage of participants
Overall Responder Rate (ORR) Comprising of PRR and Clinical Activity Responder Rate in the Study Eye
percentage of participantsVeligrotugPlacebo
Overall Responder Rate (ORR) Comprising of PRR and Clinical Activity Responder Rate in the Study Eye66.835.26
SecondaryClinical Activity Responder Rate in the Study Eye

Clinical activity responder rate in the study eye was defined as a reduction in CAS ≥2 points from baseline in the study eye (without a corresponding increase of ≥2 points in the fellow eye). Missing data were imputed with the Multiple Imputation method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Clinical Activity Responder Rate in the Study Eye
percentage of participantsVeligrotugPlacebo
Clinical Activity Responder Rate in the Study Eye92.9752.66
SecondaryDiplopia Responder Rate

Diplopia responder was defined as reduction in Gorman subjective diplopia score of ≥1 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the Multiple Imputation method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Diplopia Responder Rate
percentage of participantsVeligrotugPlacebo
Diplopia Responder Rate59.0719.89
SecondaryDiplopia Resolution Rate

Diplopia resolution was defined as reduction in Gorman subjective diplopia score to 0 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the Multiple Imputation method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Diplopia Resolution Rate
percentage of participantsVeligrotugPlacebo
Diplopia Resolution Rate49.2811.54
SecondaryPercentage of Participants With a CAS of 0 or 1 in the Study Eye

The CAS was based on 7 components: spontaneous retrobulbar pain, pain on attempted eye movements (upward, side to-side, and downward gazes), conjunctival redness, redness of the eyelids, chemosis, swelling of the caruncle or plica and swelling of the eyelids. Each component was scored as present or absent (scored as 1 or 0, respectively), and the CAS was given as the sum of the scores (range, 0 to 7, with higher scores indicating greater level of inflammation). Missing data were imputed with the Multiple Imputation method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Percentage of Participants With a CAS of 0 or 1 in the Study Eye
percentage of participantsVeligrotugPlacebo
Percentage of Participants With a CAS of 0 or 1 in the Study Eye64.5318.40

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Veligrotug0/75 (0%)7/75 (9.3%)63/75 (84%)
Placebo0/38 (0%)0/38 (0%)19/38 (50%)
Most frequent serious events
Most frequent serious events
EventVeligrotugPlacebo
ArrhythmiaCardiac disorders1/750/38
HyperthyroidismEndocrine disorders1/750/38
AppendicitisInfections and infestations1/750/38
CellulitisInfections and infestations1/750/38
Hepatic enzyme increasedInvestigations1/750/38
Peripheral sensory neuropathyNervous system disorders1/750/38
SyncopeNervous system disorders1/750/38
DepressionPsychiatric disorders1/750/38
Aortic dissectionVascular disorders1/750/38
Most frequent other events
Showing 10 of 36
Most frequent other events
EventVeligrotugPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders34/753/38
HeadacheNervous system disorders18/756/38
Infusion related reactionInjury, poisoning and procedural complications13/752/38
AlopeciaSkin and subcutaneous tissue disorders11/754/38
NauseaGastrointestinal disorders10/753/38
Ear discomfortEar and labyrinth disorders9/751/38
TinnitusEar and labyrinth disorders9/754/38
DiarrhoeaGastrointestinal disorders9/751/38
DysmenorrhoeaReproductive system and breast disorders4/340/12
AstheniaGeneral disorders5/754/38

Baseline characteristics

Modified Intent-to-Treat (mITT) population included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)VeligrotugPlaceboTotal
Mean48.9 ± 12.4249.1 ± 12.4649.0 ± 12.38
Sex: Female, Male
Sex: Female, Male(Participants)VeligrotugPlaceboTotal
Female563187
Male19726
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VeligrotugPlaceboTotal
Hispanic or Latino13720
Not Hispanic or Latino471764
Unknown or Not Reported151429
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VeligrotugPlaceboTotal
Race — Asian369
Race — Black or African American437
Race — White511970
Race — Other10515
Race — Not Reported011
Race — Missing7411
08

Study locations

53 sites
  • University of Colorado - Department of Ophthalmology
    Aurora, California 80045, United States
  • The Private Office of Raymond Douglas
    Beverly Hills, California 90210, United States
  • USC Roski Eye Institute
    Los Angeles, California 90033, United States
  • MACRO Trials, Inc.
    Los Angeles, California 90049, United States
  • Amy Patel Jain, MD
    Newport Beach, California 92260, United States
  • Byers Eye Institute/Stanford University
    Palo Alto, California 94303, United States
  • Senta Clinic
    San Diego, California 95207, United States
  • University of California, San Francisco
    San Francisco, California 94158, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Sina Medical Center
    Homestead, Florida 33034, United States
  • Med-Care Research Inc.
    Miami, Florida 33125, United States
  • Edward Jenner Research Group Center LLC
    Plantation, Florida 33317, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34231, United States
  • Vision Medical Research Inc.
    Orland Park, Illinois 60462, United States
  • University Health Diabetes, Endocrinology & Nephrology Center
    Kansas City, Kansas 64108, United States
  • KU Medical Center, University of Kansas
    Kansas City, Kansas 66103, United States
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02114, United States
  • Ophthalmic Consultants of Boston
    Weymouth, Massachusetts 02189, United States
  • Fraser Eye Care Center
    Fraser, Michigan 48026, United States
  • Kahana Oculoplastic & Orbital Surgery
    Livonia, Michigan 48152, United States
  • University of Minnesota, Department of Ophthalmology and Visual Neurosciences
    Minneapolis, Minnesota 55455, United States
  • Advanced Research International, LLC
    Las Vegas, Nevada 89144, United States
  • Rutgers-New Jersey Medical School-Newark
    Newark, New Jersey 07103, United States
  • New York Eye Ear Infirmary of Mount Sinai
    New York, New York 10003, United States
  • Baylor College of Medicine (BCM)-Ophthalmology
    Houston, Texas 77030, United States
  • Neuro-Eye Clinical Trials
    Houston, Texas 77074, United States
  • Neuro-Ophthalmology of Texas PLLC
    Houston, Texas 77074, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • West Virgina University Eye Institute
    Morgantown, West Virginia 26506, United States
  • Sydney Eye Hospital
    Sydney, 2000, Australia
  • North Shore Eye Surgery
    Sydney, 2065, Australia
  • CHU d'Angers
    Angers, 49100, France
  • CH Nice
    Nice, 06000, France
  • Centre Hospitalier National D'ophtalmologie
    Paris, 75012, France
  • AP-HP- Hopital de la Pitie Salpetriere
    Paris, 75013, France
  • Universitatsmedizin Gottingen
    Göttingen, 37075, Germany
  • Johannes Gutenberg-University Medical Center
    Mainz, 55131, Germany
  • NZOZ E-Vita
    Bialystok, 15-879, Poland
  • Specjakistyczny Osrodek Okulistyczny Oculomedica
    Bydgoszcz, 85-870, Poland
  • Santa Familia PTG Lodz
    Lodz, 90-302, Poland
  • Panstwowy Instytut Medycsny MSWiA
    Warsaw, 02-507, Poland
  • 4 Wojskowy Szpital Kliniczny z Polikinika SP ZOZ
    Wroclaw, 53-114, Poland
  • Clinica Bonanova de Cirugia Ocular
    Barcelona, 08022, Spain
  • Hospital Arruzafa
    Córdoba, 14012, Spain
  • Clinica Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Complexo Hospiralario Universitario de Santiago-Hospital Medico-Ciruxico de Conxo
    Santiago, 15706, Spain
  • Hospital Universitatio Virgen De La Macarena, Servicio de Oftalmologia
    Seville, 41071, Spain
  • Hospital Universitario Miguel Servet, Servicio de Paseo Isabel La Catdlica1
    Zaragoza, 50009, Spain
  • Northwick Park Hospital
    London, United Kingdon HA13UJ, United Kingdom
  • Western Eye Hospital Imperial College NHS trust
    London, United Kingdon NW1 5QH, United Kingdom
  • Guy's and St. Thomas NHS Trust
    London, United Kingdon SE1 7EH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jul 2024, 19 months.

Results were first posted in Aug 2026, 2 years after primary completion. A results delay was requested in Jul 2025.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 4, 2022
StartActual
Nov 16, 2022
Primary completionActual
Jul 15, 2024
CompletionActual
Mar 27, 2025
Results delay requested
Jul 14, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05176639
Lead sponsor
Viridian Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Nov 16, 2022
Primary completion
Jul 15, 2024
Completion
Mar 27, 2025
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVE1642

Start the discussion